Company intelligence / Profile preview

Synvista Therapeutics, Inc.

Montvale, New Jersey, United Statesmedia.corporate-ir.net ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Synvista Therapeutics was a biotechnology company that developed diagnostic tests and drugs to identify and treat diabetic patients at high risk for cardiovascular disease. Their lead drug candidate, alagebrium chloride, was being developed for diastolic heart failure. The company also had a program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx), with ALT-2074 reaching Phase II clinical trials. All their drug candidates appear to have been discontinued.

Therapeutic areas: EndocrinologyCardiovascularMetabolic DisordersNephrology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

alt-2074

Beyond the preview

Go deeper on Synvista Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synvista Therapeutics, Inc..

Explore the full profile